Key Highlights

• Portfolio Receipts grew 9% year-over-year to $890 million in Q3 2026, while Royalty Receipts also rose 9%.

• Full-year 2026 guidance was raised to $3,500–$3,550 million in Portfolio Receipts, up from the prior range of $3,400–$3,500 million.

• Net cash provided by Operating Activities totaled $686 million during the quarter.

• The company announced $1.9 billion in transaction value and $1.6 billion in Capital deployment as of November 3, 2026.

Royalty Pharma plc(NASDAQ:RPRX), one of the largest acquirers of biopharmaceutical royalties, reported third-quarter 2026 results on November 4, 2026, delivering 9% year-over-year growth in both Portfolio Receipts and Royalty Receipts. The company also raised its full-year 2026 guidance, reflecting continued momentum across its diversified portfolio of royalties.

Third-Quarter Financial Overview

Portfolio Receipts for Q3 2026 totaled $890 million, up from $814 million in the same period a year earlier, representing a 9% increase. Royalty Receipts, which make up the bulk of that total, came in at $883 million. The growth was driven primarily by contributions from Tremfya, Voranigo, Evrysdi, and Imdelltra. Adjusted EBITDA reached $840 million, up 8% from $779 million in Q3 2025. Net cash provided by operating activities was $686 million, compared to $703 million in the year-ago quarter. Portfolio Cash Flow stood at $673 million versus $657 million a year earlier, a 2% increase.

Among the top-contributing therapies, Vertex's cystic fibrosis Franchise generated $225 million, GSK's Trelegy contributed $89 million, and Johnson & Johnson's Tremfya rose 61% to $80 million. Roche's Evrysdi brought in $71 million, up 38%, while Servier's Voranigo climbed 65% to $55 million. On the other end, Biogen's Tysabri was essentially flat at $67 million, and GSK's Trelegy dipped 6%.

Portfolio Activity and New Royalties

Royalty Pharma continued to add to its portfolio during the quarter. The company acquired royalties on Arcutis Biotherapeutics' Zoryve for $100 million and on Takeda's Mimrylo for $100 million. As of November 3, 2026, the announced value of transactions reached $1.9 billion, with capital deployment at $1.6 billion.

CEO Pablo Legorreta highlighted the company's growing R&D co-funding activity with global biopharma partners, noting that $1 billion in such transactions had been announced so far in 2026. This represents a newer avenue of Business for Royalty Pharma beyond traditional royalty acquisitions.

Regulatory and Clinical Milestones

The quarter saw several notable FDA approvals across Royalty Pharma's portfolio. Revolution Medicines received approval for Rasonque (daraxonrasib) for metastatic pancreatic cancer. Teva's Weltruza (olanzapine LAI) was approved for schizophrenia, and Jazz and BeOne's Ziihera received approval for HER2-positive metastatic gastric cancer.

On the clinical front, Amgen's Imdelltra posted positive Phase 3 results as a first-line maintenance therapy for small cell lung cancer. Pharvaris' deucrictibant XR also delivered positive Phase 3 results for the prophylaxis of hereditary angioedema attacks. These developments provide potential future Revenue growth catalysts for the royalty portfolio.

Updated 2026 Outlook

Royalty Pharma raised its full-year 2026 Portfolio Receipts guidance to a range of $3,500 million to $3,550 million, up from the previous range of $3,400 million to $3,500 million. This revised guidance implies expected Royalty Receipts growth of 10% to 11% for the full year. Payments for operating and professional costs are projected to decline as a percentage of Portfolio Receipts, coming in at 5.5% to 6.0%, compared to 8.9% in 2025. This reduction reflects the extinguishment of the management fee following the internalization completed in May 2025. Interest payments are expected to total $350 million to $360 million for the year.

The Road Ahead

Royalty Pharma's Q3 2026 results underscore the compounding nature of its business model, with rising receipts from a diversified portfolio of therapies across multiple therapeutic areas. The raised guidance, combined with continued transaction activity and a pipeline of regulatory and clinical catalysts, positions the company for continued growth. However, the portfolio remains subject to the typical pharmaceutical risks of Patent expirations, competitive dynamics, and clinical trial outcomes that could influence future royalty streams.